Baidu
map

Circulation:更佳药物疗法对双联抗血小板治疗研究的影响

2016-10-08 xing.T MedSci原创

研究结果表明持续的噻吩吡啶类药物治疗降低心肌梗死率,不管有无进行OMT治疗,并且能够减少主要不良心血管和脑血管事件和增加出血事件。

持续的双联抗血小板治疗和最佳药物治疗(OMT)可以改善稳定型冠心病患者预后,但OMT是否会对双联抗血小板治疗产生影响尚未明确。近日,心血管领域权威杂志《Circulation》发表研究文章,旨在明确OMT是否会对双联抗血小板治疗产生影响。

在一项双盲双联抗血小板治疗的研究中,随机分配11 648例进行冠状动脉支架植入术患者,进行1年的双联抗血小板治疗,无大出血或缺血性事件发生,并且额外进行18个月持续的噻吩吡啶类药物或安慰剂治疗。OMT被定义为一个组合方案,包括他汀类药物、β-受体阻滞剂、血管紧张素转换酶抑制剂/血管紧张素受体阻断剂,所有患者每日均接受75至325mg阿司匹林治疗。主要终点事件包括心肌梗死、主要不良心脑血管事件的发生,对闭塞性动脉全身运用链激酶和组织型纤溶酶原激活剂导致中度或严重出血事件。

随机分配的11643例患者拥有 完整的用药数据,63%的患者采用OMT治疗,在12个月到30个月期间,相比于安慰剂组,持续的噻吩吡啶类药物治疗可降低两组患者的心肌梗死发生率(OMT治疗组2.1% vs 3.3%,风险比为0.64;95%可信区间为0.48–0.86;P=0.003;未进行OMT治疗组2.2% vs 5.2%,风险比为0.41;95%可信区间为0.29–0.58;P<0.001;P=0.103)。


持续噻吩吡啶类药物治疗与安慰剂比,OMT组的主要不良心脑血管事件的发生率分别为4.2%和5.0%(风险比为0.82;95%可信区间为0.66–1.02;P = 0.077),未进行OMT治疗组分别为4.5%和7.0%(风险比为0.63;95%可信区间为0.49–0.82;P<0.001;P=0.250);

OMT组患者,与服用安慰剂的患者(1%)相比,噻吩吡啶类药物治疗的出血率为2.2%(风险比为2.13;95%可信区间为1.43–3.17;P<0.001),在未进行OMT治疗组的患者,噻吩吡啶类药物治疗患者和安慰剂治疗患者出血率分别为2.8%和2.2%(风险比为1.30;95%可信区间为0.88–1.92;P=0.189;P=0.073)。

总的来说,相比于未进行OMT治疗组,OMT治疗患者具有较低的心肌梗死(2.7% vs 3.7%, P=0.003)、主要不良心脑血管事件(4.6% vs 5.7%,P=0.007)、出血(1.6% vs 2.5%,P<0.001)的发生率,而支架内血栓形成率(0.8% vs 1%,P=0.171)和死亡(1.6% vs 1.9%,P=0.155)没有显着差异。

研究结果表明,不管有无进行OMT治疗,持续的噻吩吡啶类药物治疗降低心肌梗死率,并且能够减少主要不良心血管和脑血管事件和增加出血事件。

原始出处:

Charles D. Resor,et al. Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study.Circulation.2016.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2034285, encodeId=e282203428577, content=<a href='/topic/show?id=33d28e81604' target=_blank style='color:#2F92EE;'>#药物疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87816, encryptionId=33d28e81604, topicName=药物疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Mon Feb 27 18:12:00 CST 2017, time=2017-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009518, encodeId=bcd8200951895, content=<a href='/topic/show?id=4f133e56590' target=_blank style='color:#2F92EE;'>#双联抗血小板#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37565, encryptionId=4f133e56590, topicName=双联抗血小板)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Fri Dec 23 19:12:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145725, encodeId=3cc9145e250b, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:43:52 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145724, encodeId=5441145e2473, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:43:40 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145440, encodeId=dd9914544051, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 20:21:26 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515594, encodeId=dfd215155942c, content=<a href='/topic/show?id=59ab3e5660f' target=_blank style='color:#2F92EE;'>#双联抗血小板治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37566, encryptionId=59ab3e5660f, topicName=双联抗血小板治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Oct 09 15:12:00 CST 2016, time=2016-10-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2034285, encodeId=e282203428577, content=<a href='/topic/show?id=33d28e81604' target=_blank style='color:#2F92EE;'>#药物疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87816, encryptionId=33d28e81604, topicName=药物疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Mon Feb 27 18:12:00 CST 2017, time=2017-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009518, encodeId=bcd8200951895, content=<a href='/topic/show?id=4f133e56590' target=_blank style='color:#2F92EE;'>#双联抗血小板#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37565, encryptionId=4f133e56590, topicName=双联抗血小板)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Fri Dec 23 19:12:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145725, encodeId=3cc9145e250b, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:43:52 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145724, encodeId=5441145e2473, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:43:40 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145440, encodeId=dd9914544051, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 20:21:26 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515594, encodeId=dfd215155942c, content=<a href='/topic/show?id=59ab3e5660f' target=_blank style='color:#2F92EE;'>#双联抗血小板治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37566, encryptionId=59ab3e5660f, topicName=双联抗血小板治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Oct 09 15:12:00 CST 2016, time=2016-10-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2034285, encodeId=e282203428577, content=<a href='/topic/show?id=33d28e81604' target=_blank style='color:#2F92EE;'>#药物疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87816, encryptionId=33d28e81604, topicName=药物疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Mon Feb 27 18:12:00 CST 2017, time=2017-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009518, encodeId=bcd8200951895, content=<a href='/topic/show?id=4f133e56590' target=_blank style='color:#2F92EE;'>#双联抗血小板#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37565, encryptionId=4f133e56590, topicName=双联抗血小板)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Fri Dec 23 19:12:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145725, encodeId=3cc9145e250b, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:43:52 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145724, encodeId=5441145e2473, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:43:40 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145440, encodeId=dd9914544051, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 20:21:26 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515594, encodeId=dfd215155942c, content=<a href='/topic/show?id=59ab3e5660f' target=_blank style='color:#2F92EE;'>#双联抗血小板治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37566, encryptionId=59ab3e5660f, topicName=双联抗血小板治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Oct 09 15:12:00 CST 2016, time=2016-10-09, status=1, ipAttribution=)]
    2016-10-11 知难而进

    继续关注!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2034285, encodeId=e282203428577, content=<a href='/topic/show?id=33d28e81604' target=_blank style='color:#2F92EE;'>#药物疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87816, encryptionId=33d28e81604, topicName=药物疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Mon Feb 27 18:12:00 CST 2017, time=2017-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009518, encodeId=bcd8200951895, content=<a href='/topic/show?id=4f133e56590' target=_blank style='color:#2F92EE;'>#双联抗血小板#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37565, encryptionId=4f133e56590, topicName=双联抗血小板)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Fri Dec 23 19:12:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145725, encodeId=3cc9145e250b, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:43:52 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145724, encodeId=5441145e2473, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:43:40 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145440, encodeId=dd9914544051, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 20:21:26 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515594, encodeId=dfd215155942c, content=<a href='/topic/show?id=59ab3e5660f' target=_blank style='color:#2F92EE;'>#双联抗血小板治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37566, encryptionId=59ab3e5660f, topicName=双联抗血小板治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Oct 09 15:12:00 CST 2016, time=2016-10-09, status=1, ipAttribution=)]
    2016-10-11 知难而进

    谢谢分享!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2034285, encodeId=e282203428577, content=<a href='/topic/show?id=33d28e81604' target=_blank style='color:#2F92EE;'>#药物疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87816, encryptionId=33d28e81604, topicName=药物疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Mon Feb 27 18:12:00 CST 2017, time=2017-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009518, encodeId=bcd8200951895, content=<a href='/topic/show?id=4f133e56590' target=_blank style='color:#2F92EE;'>#双联抗血小板#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37565, encryptionId=4f133e56590, topicName=双联抗血小板)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Fri Dec 23 19:12:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145725, encodeId=3cc9145e250b, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:43:52 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145724, encodeId=5441145e2473, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:43:40 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145440, encodeId=dd9914544051, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 20:21:26 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515594, encodeId=dfd215155942c, content=<a href='/topic/show?id=59ab3e5660f' target=_blank style='color:#2F92EE;'>#双联抗血小板治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37566, encryptionId=59ab3e5660f, topicName=双联抗血小板治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Oct 09 15:12:00 CST 2016, time=2016-10-09, status=1, ipAttribution=)]
    2016-10-11 1e10c84am36(暂无匿称)

    好文章,受益

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2034285, encodeId=e282203428577, content=<a href='/topic/show?id=33d28e81604' target=_blank style='color:#2F92EE;'>#药物疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87816, encryptionId=33d28e81604, topicName=药物疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Mon Feb 27 18:12:00 CST 2017, time=2017-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009518, encodeId=bcd8200951895, content=<a href='/topic/show?id=4f133e56590' target=_blank style='color:#2F92EE;'>#双联抗血小板#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37565, encryptionId=4f133e56590, topicName=双联抗血小板)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Fri Dec 23 19:12:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145725, encodeId=3cc9145e250b, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:43:52 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145724, encodeId=5441145e2473, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 21:43:40 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145440, encodeId=dd9914544051, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 20:21:26 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515594, encodeId=dfd215155942c, content=<a href='/topic/show?id=59ab3e5660f' target=_blank style='color:#2F92EE;'>#双联抗血小板治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37566, encryptionId=59ab3e5660f, topicName=双联抗血小板治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Oct 09 15:12:00 CST 2016, time=2016-10-09, status=1, ipAttribution=)]

相关资讯

AHA 2014:郭艺芳:冠脉药物支架术后双抗治疗需多久?

按照现行指南建议,冠状动脉植入药物支架术后患者需要接受为期12个月阿司匹林与氯吡格雷(或其他噻吩吡啶类药物)双联抗血小板治疔。继续延长双抗时间是否能继续获益?缩短双抗时间是否会增加支架内栓风险?这些问题均受到广泛关注,但迄今尚无明确答案。本届AHA年会期间将公布3项相关研究,其中双联抗血小板研究(DAPT)与药物支架术后6个月双联抗血小板治疗安全性和有效性研究(ISAR-SAFE)最值得关注,

PCI术后双抗到底需多久?

PCI术后DAPT时间:仍无定论 经皮冠状动脉介入治疗(PCI)置入药物洗脱支架(DES)后,由于术后血管损伤修复、支架内皮覆盖需要一定的时间,因而有效的双联抗血小板治疗(DAPT)十分必要,以预防晚期或极晚期支架内血栓形成,减少缺血性心血管事件的发生。 上海交通大学医学院附属瑞金医院沈卫峰教授介绍,近年来人们致力于探讨DAPT最佳时间间期,以达到获益与出血风险的平衡。目前大多

如何权衡不同双联抗血小板疗程的利弊?

《内科学年鉴》(Ann Intern Med)于5月26日发表了一项有关双联抗血小板治疗的荟萃分析。该研究主要探索了药物洗脱支架介入术后双联抗血小板治疗的适宜疗程。 研究者指出虽然人们开展了大量双联抗血小板治疗(DAPT)的临床试验,但对于药物洗脱支架(DES)介入术后DAPT疗程存在争议,即DAPT疗程究竟长一些还是短一些更好。为解答这个问题,研

JACC:药物洗脱支架后双联抗血小板治疗时间是否越长越好?

经皮冠状动脉介入术(药物洗脱支架DES)后进行双联抗血小板(DAPT)可以有效地预防支架内血栓形成。期间,阻止或中断DAPT会升高缺血风险,包括支架内血栓,尤其是在DES植入后的第一周内。然而,是不是进行DAPT时间越长越好呢?这个问题一直困扰着临床医生。因此,美国纽约西奈山伊坎医学院The Zena and Michael A. Wiener 心血管研究所的Gennaro Giustino博士等

Baidu
map
Baidu
map
Baidu
map